In 2024, Johnson & Johnson spent more than 17 billion U.S. dollars on research and development. This is a significant increase compared to 2014 when the company spent 8.5 billion dollars on R&D. Johnson & Johnson’s global positioning Globally there are several top pharmaceutical companies, however Johnson & Johnson stands out about many of them with research and development being a top priority for the company. Therefore, it is no surprise that J&J is one of the top three pharmaceutical companies based on its R&D spending. Johnson & Johnson also has one of the largest current research and development pipelines among global pharmaceutical companies. The importance of pharmaceutical R&D Among all industries, pharmaceuticals and biotechnology are those with the largest investments in research and development. Pharmaceutical research and development is the process in which pharmaceutical companies apply research to generate new pharmaceutical products which in most cases involves clinical trials. The number of drugs being researched and developed globally has never been higher than recently. However, the success rate for new drugs in development is only around 10 percent.

This statistic shows Johnson & Johnson's research and development expenditure as a percent of sales from 2005 to 2024. Johnson & Johnson is a company specialized in pharmaceuticals, medical devices and diagnostics. The company is headquartered in New Brunswick, New Jersey. In 2024, the company's R&D expenditure represented some **** percent of its total sales.

In 2026, Swiss-based Roche is projected to spend 14 billion U.S. dollars on pharmaceutical research and development. Other companies with high projected R&D expenditures are Merck, Pfizer, and Johnson & Johnson. Expenditure per country The United States is projected to spend between 605 and 635 billion U.S. dollars on medicine in 2025. Current expenditures, as well as future estimates for the United States, are significantly higher than those of other high-spending countries, such as Japan and Germany. Japan, for example, is expected to spend between 75 and 95 billion U.S. dollars on pharmaceuticals that year. Johnson & Johnson Johnson & Johnson is a major pharmaceutical company, which had a total employee count of about 135 thousand people in 2020, headquartered in New Jersey, United States. The multinational company produces various pharmaceutical products, including Telara, Remicade, Zytiga, Imbruvica, and Darzalex. In 2020, Stelara was Johnson & Johnson’s top drug, earning the company almost 7.7 billion U.S. dollars in revenue. However, Johnson & Johnson has also significant medical devices and consumer products divisions.

The top 50 pharmaceutical companies by prescription sales in 2024 – and their research and development (R&D) spending – included big names such as Johnson & Johnson, Novartis, and AbbVie. During that year, Johnson & Johnson's Rx sales were approximately **** billion U.S. dollars. Thus, the American pharma giant was both the largest pharmaceutical company based on pure pharma revenue worldwide and the second ranked pharmaceutical company based on R&D spending. Johnson & Johnson spent over ** billion U.S. dollars on R&D in that year. Pharmaceutical R&D spending Research and development in the pharmaceutical industry involves the identification and development of compounds used to make new drugs. The pharmaceutical industry has the largest percentage of spending attributable to R&D among all industries. Research and development spending in the pharmaceutical industry around the world is increasing over time. However, there have been variations in the growth of research and development spending with a peak during the pandemic years 2020 and 2021. New pharmaceutical products The goal of R&D is to produce new drugs and compounds. Globally, the U.S. pharmaceutical industry created the largest number of new drugs and compounds between 2019 and 2023, followed by Europe. Among U.S. pharmaceutical companies, there are various levels of success for new drugs, depending on the phase of development. The data shows that between phase I and II alone, already over half of all drugs are failing.

Novo Nordisk's Cagrisema was the most valuable research and development project in the pharmaceutical industry worldwide, based on its net present value (NPV) of ** billion U.S. dollars, as of May 2024. Global R&D spending In 2023, global pharmaceutical industry expenditures for research and development amounted to over *** billion U.S. dollars. Total global R&D expenditures have been increasing with each consecutive year since 2012. Some of 2023’s leading pharmaceutical companies, in terms of R&D spending, included Merck, Roche, and Johnson & Johnson. Pfizer Pfizer is one of the world’s largest pharmaceutical corporations. Based in New York City, the American company generates a considerable amount of its revenue in the United States. In 2023, Pfizer earned some ** billion U.S. dollars’ worth of revenue in its U.S. American submarket, and around ** billion in emerging markets.

Cette statistique présente les dépenses engagées par Johnson & Johnson en recherche et développement (R&D) entre 2005 et 2022, en millions de dollars des États-Unis. Johnson & Johnson est une société multinationale spécialisée dans les produits pharmaceutiques, les appareils médicaux et les biens de consommation. Cette entreprise est basée à New Brunswick, dans le New Jersey. En 222, les dépenses engagées en R&D de Johnson & Johnson s'élevaient à dépassaient les 14 milliards de dollars.

Cette statistique présente le budget alloué à la recherche et au développement (R&D) chez Johnson & Johnson, en part du chiffre d'affaires du groupe, entre 2005 et 2023. Sur l'ensemble de la période mesurée, les dépenses en R&D de Johnson & Johnson ont ainsi progressé, représentant désormais presque ** % du chiffre d'affaires du groupe.